Neurology

Intake of fish high in omega-3 fatty acids could help reduce the risk of developing multiple sclerosis or clinically isolated syndrome.

A more detailed look at gray matter atrophy may hold clues to multiple sclerosis progression.

Novartis makes a move in the digital health field, and we may see more traction with pharmacological treatments and technological platforms.

Targeting an energy-related molecule could prevent the onset of autoimmune diseases.

An enzyme blockade could assist remyelination in patients with peripheral nerve damage.

Stem cell treatments improved muscle strength and disability among patients with multiple sclerosis.

Daclizumab (Zinbryta) may cause brain inflammation among patients with relapsing multiple sclerosis.

March is multiple sclerosis awareness month.

Ozanimod evaluated as a treatment for multiple sclerosis and inflammatory bowel disease.

March is MS awareness month, spotlighting this chronic, progressive disease that is growing in prevalence.

The gut microbiome may play a key role impact the severity of multiple sclerosis symptoms.

Deep transcranial stimulation could provide more relief from fatigue among multiple sclerosis patients compared with other treatments.

A popular multiple sclerosis drug may increase the risk of a potentially-fatal brain infection.

Less serious adverse events remain a concern for patients treated for chronic diseases.

Balance and eye movement exercise improved quality of life for patients with multiple sclerosis.

Officials with the FDA have approved Novartis' glatiramer acetate injection (Glatopa) 40-mg/mL for the treatment of multiple sclerosis (MS).

A cytokine may protect myelin against attacks by the immune system in multiple sclerosis.

A number of landmark clinical studies in the field of MS have been published, shaping how the disease is treated.

The RAISE Family Caregivers Act aids individuals taking care of loved ones with chronic diseases.

A look at last week's top stories in the world of pharmacy.

A look at last week's top stories in the world of pharmacy.

A multiple sclerosis drug may be used as a PET scan tracer agent to image demyelination.

Controlling cholesterol synthesis expression may reduce walking disability in patients with multiple sclerosis.

A number of landmark clinical studies in the field of MS have been published, shaping how the disease is treated.

An investigational immunotherapy for multiple sclerosis targets Epstein-Barr virus.